BioIntel is now The Catalyst Brief.
The Catalyst Brief
Coverage

Regulatory & Policy

FDA actions, approvals, policy shifts and compliance: how the rules change timelines and probability.

Page 38 of 39

Archive

The NIH's Crisis of Integrity: Four Leaders Resign Over Scientific Interference and CensorshipJan 11, 2026

The NIH's Crisis of Integrity: Four Leaders Resign Over Scientific Interference and Censorship

The National Institutes of Health (NIH) has been a cornerstone of biomedical research innovation and public health advancement. However, recent resignations by four senior leaders spotlight serious concerns over editorial interference and censorship, raising questions about the organization's commitment to scientific rigor and transparency. This development underscores a growing apprehension within the biomedical community regarding governance and autonomy at one of the world's premier research institutions.

The Catalyst Brief
House Passes Extension of ACA Subsidies Amid Growing Bipartisan SupportJan 8, 2026

House Passes Extension of ACA Subsidies Amid Growing Bipartisan Support

With increasing backing from House Republicans, particularly those representing vulnerable districts, the subsidy extension aims to ease rising insurance premium costs. This development marks a pivotal moment in ongoing healthcare policy negotiations for 2026.

The Catalyst Brief
New U.S. Dietary Guidelines Stir Debate Amid Panel's Industry Financial TiesJan 7, 2026

New U.S. Dietary Guidelines Stir Debate Amid Panel's Industry Financial Ties

The latest dietary guidelines recommend increased protein and dairy consumption while reducing sugar and processed food intake. However, scrutiny arises due to the advisory panel's financial ties to industries that benefit from these changes. This controversy comes amid criticism from figures like Robert F. Kennedy Jr. regarding corporate influence in public health policies.

The Catalyst Brief
FDA Eases Oversight on AI-Enabled Devices and Wearables to Promote InnovationJan 6, 2026

FDA Eases Oversight on AI-Enabled Devices and Wearables to Promote Innovation

In a significant policy shift aimed at accelerating innovation and access, the FDA will reduce its regulatory burden on AI-powered and wearable health technology. This move reflects a strategic decision to facilitate the expansion of AI use in healthcare while balancing safety and efficacy.

The Catalyst Brief
Federal Health Officials Slash Childhood Vaccine RecommendationsJan 6, 2026

Federal Health Officials Slash Childhood Vaccine Recommendations

The number of recommended childhood vaccinations has been significantly trimmed, raising concerns among health experts about the new vaccine schedule's impact on children's near- and long-term health. This major policy change alters the longstanding immunization framework.

The Catalyst Brief

Other beats

AI in Drug Discovery

Machine learning, predictive models and computational biology: how AI is changing discovery workflows and probability of success.

Biopharmaceutical Industry

Drug development, clinical trials and industry dynamics. What changes timelines, risk and competitive positioning.

Biotech Innovation

Gene therapy, CRISPR, synthetic biology and emerging platforms. Separating what is real from what is hype, and what actually translates.

Healthcare Investment

Where capital is flowing and why the tape moves, across funding rounds, M&A, IPOs and market analysis.

Medical Technology

Digital health, diagnostics and medical devices, and the signals that matter for adoption, reimbursement and outcomes.